Eledon Pharmaceuticals, Inc. (ELDN)
ELDN moved a median of -0.38% 30 minutes after news, and 0.00% by the close. How ELDN actually reacts to news — the realized, point-in-time move the market made, measured across 196 labeled events over the last three years with zero look-ahead.
ELDN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 188 |
| 30-min | -0.38% | 38% | 194 |
| 60-min | -0.41% | 42% | 196 |
| to close | 0.00% | 47% | 193 |
| Middle 50% of ELDN reactions | -1.79% to +1.14% |
|---|---|
| Median reaction (30-min) | -0.38% |
| Measured reactions | 196 |
Half of all Eledon Pharmaceuticals, Inc. news events land between -1.79% and +1.14% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ELDN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 13 | -0.98% | 23% | -1.56% |
| Rating reiterations | 18 | +1.36% | 72% | -1.28% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ELDN ranks against every other measured name →
That’s how ELDN usually reacts — get an email when it moves on news →Email me when ELDN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ELDN's baseline. Nothing else.
Recent ELDN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting | Press release | GlobeNewswire | -0.79% | -3.16% | |
| Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society | Press release | GlobeNewswire | -0.58% | +5.09% | |
| Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society | Press release | GlobeNewswire | -0.28% | -4.41% | |
| Form S-8 Eledon Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | -2.32% | -2.98% | |
| Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 | Press release | GlobeNewswire | -0.65% | -4.56% | |
| Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | -0.28% | -1.67% | |
| Form 10-Q Eledon Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.28% | -1.67% | |
| Form 8-K Eledon Pharmaceuticals, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -0.28% | -1.67% | |
| A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up | Press release | Canada Newswire | +0.00% | -0.75% | |
| The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy | Press release | Canada Newswire | +0.51% | +6.58% | |
| Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus | Press release | GlobeNewswire | +4.26% | -4.51% | |
| Form 8-K Eledon Pharmaceuticals, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +3.04% | +4.50% | |
| Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine | Press release | GlobeNewswire | +0.68% | -2.19% | |
| Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions | Press release | GlobeNewswire | -0.56% | -5.01% | |
| Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress | Press release | GlobeNewswire | +0.53% | +2.64% | |
| Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +0.00% | +0.77% | |
| Form 10-Q Eledon Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.77% | |
| Form 8-K Eledon Pharmaceuticals, For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.77% | |
| Form EFFECT Eledon Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | -0.00% | +2.36% | |
| Form S-3 Eledon Pharmaceuticals, | SEC filing · Form S-3 | SEC EDGAR | +0.55% | +3.00% | |
| Form ARS Eledon Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.27% | +0.82% | |
| Form DEF 14A Eledon Pharmaceuticals, For: Jun 18 | SEC filing · Form DEF | SEC EDGAR | +0.27% | +0.82% | |
| Form DEFA14A Eledon Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | +0.27% | +0.82% | |
| Form PRE 14A Eledon Pharmaceuticals, For: Jun 18 | SEC filing · Form PRE | SEC EDGAR | -1.57% | -5.71% | |
| Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results | Press release | GlobeNewswire | +1.60% | +0.35% | |
| Form 10-K Eledon Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.60% | +0.35% | |
| Form 8-K Eledon Pharmaceuticals, For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +1.60% | +0.35% | |
| Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine | Press release | GlobeNewswire | +2.17% | -0.72% | |
| Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation | Press release | GlobeNewswire | -0.67% | -3.33% | |
| Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference | Press release | GlobeNewswire | +5.32% | +3.15% | |
| Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | +0.84% | +10.61% | |
| Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium | Press release | GlobeNewswire | -1.33% | -4.89% | |
| Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook | Press release | GlobeNewswire | +1.09% | +1.17% | |
| Form 8-K Eledon Pharmaceuticals, For: Dec 30 | SEC filing · Form 8-K | SEC EDGAR | -3.01% | -0.60% | |
| The End of Shots? 5 Biotech Stocks Rethinking Diabetes | Press release | PR Newswire | -0.66% | +0.00% | |
| Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference | Press release | GlobeNewswire | +1.88% | -4.38% | |
| Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine | Press release | GlobeNewswire | +6.50% | +0.00% | |
| Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -5.00% | -10.00% | |
| Form 10-Q Eledon Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.00% | -10.00% | |
| Form 8-K Eledon Pharmaceuticals, For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | -5.00% | -10.00% | |
| Form 8-K Eledon Pharmaceuticals, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -4.74% | — | |
| Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -0.04% | +1.07% | |
| Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants | Press release | GlobeNewswire | -0.04% | +1.07% | |
| Form 8-K Eledon Pharmaceuticals, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | +3.00% | |
| Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting | Press release | GlobeNewswire | -0.25% | +3.00% | |
| Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference | Press release | GlobeNewswire | -1.44% | -3.36% | |
| Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting | Press release | GlobeNewswire | +2.71% | +18.21% | |
| Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association | Press release | GlobeNewswire | +0.20% | +0.41% | |
| Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025 | Press release | GlobeNewswire | -0.78% | +0.78% | |
| Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results | Press release | GlobeNewswire | +0.00% | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ELDN section they belong to.
Where else ELDN is measured.
ELDN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Eledon Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled ELDN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 196 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 38% of ELDN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ELDN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.